Daiichi Sankyo
DSKYFDrugs in Pipeline
122
Phase 3 Programs
71
Upcoming Catalysts
9
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
11 upcoming, 0 past
How DSKYF's past catalysts played out
DS-1062a
Non-small Cell Lung Cancer
Dalteparin
Venous Thromboembolism (VTE)
DS-5565
Pain Associated With Fibromyalgia
Ifinatamab deruxtecan
Esophageal Squamous Cell Carcinoma
Chemotherapy
Acute Myeloid Leukemia
Mirogabalin
Diabetic Peripheral Neuropathic Pain
Colesevelam hydrochloride
Type 2 Diabetes
DU-176b (edoxaban)
Venous Thromboembolism
losartan potassium
Essential Hypertension
Olmesartan medoxomil
Atherosclerosis
ofloxacin otic solution 0.3%
Otitis Media
exatecan mesylate
Esophageal Cancer
Pemetrexed
Metastatic Non Small Cell Lung Cancer
Colesevelam HCl
Type 2 Diabetes
DU-176b 30mg
Non-valvular Atrial Fibrillation
Dato-DXd
Urothelial Cancer
gemcitabine hydrochloride
Pancreatic Cancer
Hydrochlorothiazide
Hypertension
warfarin tablets
Stroke
Pexidartinib
Tenosynovial Giant Cell Tumor
Topotecan
Small Cell Lung Cancer
Standard of Care (SOC)
Cardiac Disease
Amlodipine
Hypertension
Welchol
Type 2 Diabetes Mellitus
DU-176b
Venous Thromboembolism
Ramucirumab
Gastric Cancer, Adenocarcinoma
CS-8958
Influenza, Human
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets
Essential Hypertension
Eplerenone
Essential Hypertension
Eribulin
Breast Cancer
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets
Essential Hypertension
Pregabalin
Pain Associated With Fibromyalgia
Docetaxel
Non-small Cell Lung Cancer
Standard of Care
Venous Thromboembolism (VTE)
nitrendipine + hydrochlorothiazide, if necessary
Isolated Systolic Hypertension
Pioglitazone
Type 2 Diabetes Mellitus
Carboplatin
Extensive Stage-small Cell Lung Cancer
Metformin HCl tablets and Colesevelam tablets
Type 2 Diabetes Mellitus
Clopidogrel
Atrial Fibrillation
Olmesartan medoxomil 40 mg - Amlodipine 10 mg
Essential Hypertension
VKA-Based Regimen
Atrial Fibrillation
Olmesartan medoxomil tablets low dose
Metabolic Syndrome
T-DM1
HER2-Positive Primary Breast Cancer
15mg DU-176b
Venous Thromboembolism
Colesevelam
Type 2 Diabetes
edoxaban tosylate(DU-176b)
Venous Thromboembolism
Salvage Chemotherapy
AML
olmesartan medoxomil + amlodipine + hydroclororthiazide
Essential Hypertension
enoxaparin sodium
Venous Thromboembolism
Tivantinib
Metastatic Colorectal Cancer
Enoxaparin
Pulmonary Embolism
Denosumab
Osteoporosis
DU-176b 15mg
Venous Thromboembolism
olmesartan medoxomil + hydrochlorothiazide
Essential Hypertension
cevimeline hydrochloride
Head and Neck Cancer
T-DXd
Advanced Cancer
Quizartinib
Leukemia
DS-8201a
Neoplasm, Gastrointestinal
Trastuzumab Deruxtecan
Gastric Cancer
CS-3150
Essential Hypertension
Patritumab Deruxtecan
Nonsquamous Non-small Cell Lung Cancer
R-DXd
Solid Cancer
Edoxaban-based Regimen
Atrial Fibrillation
pembrolizumab
Non-small Cell Lung Cancer
Transdermal Patch
Trauma
Rivoglitazone
Type 2 Diabetes
Warfarin
Atrial Fibrillation
Datopotamab Deruxtecan
Metastatic Non Small Cell Lung Cancer
Capecitabine
Breast Cancer
olmesartan medoxomil + hydrochlorothiazide, if necessary
Essential Hypertension
edoxaban
Prevention
Paclitaxel
Ovarian Cancer Stage IIIC
Patritumab Deruxtecan (Fixed dose)
Non-Small Cell Lung Cancer Metastatic
Carperitide
Heart Failure, Congestive
Raludotatug deruxtecan
Advanced Solid Tumor
DS-5670a
Covid19
HER3-DXd
Advanced Solid Tumor
SUN13834
Atopic Dermatitis
CS-7017
Advanced Non-small Cell Lung Cancer (NSCLC)
DU-176b tablets
Atrial Fibrillation
DS-7011a
Systemic Lupus Erythematosus
piclozotan
Parkinson's Disease
5 mg ASB17061
Atopic Dermatitis
CS7017 tablets
Metastatic Non-small Cell Lung Cancer
soblidotin
Lung Cancer
Temozolomide
Patients With Newly Diagnosed Glioblastoma
DS-1211b
Pseudoxanthoma Elasticum
DS-8201a 5.4 mg/kg Q3W
Advanced Colorectal Cancer
DS-8500a 25 mg
Type 2 Diabetes Mellitus
Pregabalin capsules
Pain
VN-0200
Respiratory Syncytial Virus Infections
DS-3939a
Advanced Solid Tumor
Pactimibe, CS-505
Coronary Heart Disease
Valemetostat Tosylate
Adult T-cell Leukemia/Lymphoma
Quizartinib High Dose
Acute Myeloid Leukemia
CS7017
Colorectal Cancer
DS-5141b
Duchenne Muscular Dystrophy
Warfarin potassium tablets
Atrial Fibrillation
DS-1040b
Acute Ischemic Stroke
edoxaban tosylate
Deep Vein Thrombosis
CS-917
Diabetes Mellitus, Type 2
CS-1008 2 mg/kg
Advanced Hepatocellular Carcinoma
DS-1001b
WHO Grade II Glioma
AC220
Leukemia, Myeloid, Acute
Compound AC220
Acute Myeloid Leukemia
Sitagliptin 100 mg
Type 2 Diabetes Mellitus
SUN13837 injection
Acute Spinal Cord Injury
Ifinatamab deruxtecan (I-DXd)
Advanced Solid Tumor
Edoxaban (DU-176b)
Atrial Fibrillation
CS-1008 (humanized anti-DR5 antibody)
Pancreatic Cancer
DJ-927
Colorectal Cancer
U3-1287
NSCLC (Advanced Non-small Cell Lung Cancer)
10mg DS-8500a tablet
Type 2 Diabetes Mellitus
Fludarabine
Acute Myeloid Leukemia
DS3790a
Hematological Malignancies
DS-5565 tablet
Diabetic Peripheral Neuropathy
SUN11031 20 μg/kg
Cachexia
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Thrombosis
PLX3397
Hodgkin Lymphoma
Rivoglitazone HCl
Type 2 Diabetes
Aspirin
Peripheral Arterial Disease
CS-1008
Non-small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DS-1062a | Phase 3 | Non-small Cell Lung Cancer | - | - |
Dalteparin | Phase 3 | Venous Thromboembolism (VTE) | - | - |
DS-5565 | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Ifinatamab deruxtecan | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
Chemotherapy | Phase 3 | Acute Myeloid Leukemia | - | - |
Mirogabalin | Phase 3 | Diabetic Peripheral Neuropathic Pain | - | - |
Colesevelam hydrochloride | Phase 3 | Type 2 Diabetes | - | - |
DU-176b (edoxaban) | Phase 3 | Venous Thromboembolism | - | - |
losartan potassium | Phase 3 | Essential Hypertension | - | - |
Olmesartan medoxomil | Phase 3 | Atherosclerosis | - | - |
ofloxacin otic solution 0.3% | Phase 3 | Otitis Media | - | - |
exatecan mesylate | Phase 3 | Esophageal Cancer | - | - |
Pemetrexed | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
Colesevelam HCl | Phase 3 | Type 2 Diabetes | - | - |
DU-176b 30mg | Phase 3 | Non-valvular Atrial Fibrillation | - | - |
Dato-DXd | Phase 3 | Urothelial Cancer | - | - |
gemcitabine hydrochloride | Phase 3 | Pancreatic Cancer | - | - |
Hydrochlorothiazide | Phase 3 | Hypertension | - | - |
warfarin tablets | Phase 3 | Stroke | - | - |
Pexidartinib | Phase 3 | Tenosynovial Giant Cell Tumor | - | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - | - |
Standard of Care (SOC) | Phase 3 | Cardiac Disease | - | - |
Amlodipine | Phase 3 | Hypertension | - | - |
Welchol | Phase 3 | Type 2 Diabetes Mellitus | - | - |
DU-176b | Phase 3 | Venous Thromboembolism | - | - |
Ramucirumab | Phase 3 | Gastric Cancer, Adenocarcinoma | - | - |
CS-8958 | Phase 3 | Influenza, Human | - | - |
olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets | Phase 3 | Essential Hypertension | - | - |
Eplerenone | Phase 3 | Essential Hypertension | - | - |
Eribulin | Phase 3 | Breast Cancer | - | - |
olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets | Phase 3 | Essential Hypertension | - | - |
Pregabalin | Phase 3 | Pain Associated With Fibromyalgia | - | - |
Docetaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
Standard of Care | Phase 3 | Venous Thromboembolism (VTE) | - | - |
nitrendipine + hydrochlorothiazide, if necessary | Phase 3 | Isolated Systolic Hypertension | - | - |
Pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Carboplatin | Phase 3 | Extensive Stage-small Cell Lung Cancer | - | - |
Metformin HCl tablets and Colesevelam tablets | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Clopidogrel | Phase 3 | Atrial Fibrillation | - | - |
Olmesartan medoxomil 40 mg - Amlodipine 10 mg | Phase 3 | Essential Hypertension | - | - |
VKA-Based Regimen | Phase 3 | Atrial Fibrillation | - | - |
Olmesartan medoxomil tablets low dose | Phase 3 | Metabolic Syndrome | - | - |
T-DM1 | Phase 3 | HER2-Positive Primary Breast Cancer | - | - |
15mg DU-176b | Phase 3 | Venous Thromboembolism | - | - |
Colesevelam | Phase 3 | Type 2 Diabetes | - | - |
edoxaban tosylate(DU-176b) | Phase 3 | Venous Thromboembolism | - | - |
Salvage Chemotherapy | Phase 3 | AML | - | - |
olmesartan medoxomil + amlodipine + hydroclororthiazide | Phase 3 | Essential Hypertension | - | - |
enoxaparin sodium | Phase 3 | Venous Thromboembolism | - | - |
Tivantinib | Phase 3 | Metastatic Colorectal Cancer | - | - |
Enoxaparin | Phase 3 | Pulmonary Embolism | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
DU-176b 15mg | Phase 3 | Venous Thromboembolism | - | - |
olmesartan medoxomil + hydrochlorothiazide | Phase 3 | Essential Hypertension | - | - |
cevimeline hydrochloride | Phase 3 | Head and Neck Cancer | - | - |
T-DXd | Phase 3 | Advanced Cancer | - | - |
Quizartinib | Phase 3 | Leukemia | - | - |
DS-8201a | Phase 3 | Neoplasm, Gastrointestinal | - | - |
Trastuzumab Deruxtecan | Phase 3 | Gastric Cancer | - | - |
CS-3150 | Phase 3 | Essential Hypertension | - | - |
Patritumab Deruxtecan | Phase 3 | Nonsquamous Non-small Cell Lung Cancer | - | - |
R-DXd | Phase 3 | Solid Cancer | - | - |
Edoxaban-based Regimen | Phase 3 | Atrial Fibrillation | - | - |
pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | - | - |
Transdermal Patch | Phase 3 | Trauma | - | - |
Rivoglitazone | Phase 3 | Type 2 Diabetes | - | - |
Warfarin | Phase 3 | Atrial Fibrillation | - | - |
Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer | - | - |
Capecitabine | Phase 3 | Breast Cancer | - | - |
olmesartan medoxomil + hydrochlorothiazide, if necessary | Phase 3 | Essential Hypertension | - | - |
edoxaban | Phase 3 | Prevention | - | - |
Paclitaxel | Phase 2 | Ovarian Cancer Stage IIIC | - | - |
Patritumab Deruxtecan (Fixed dose) | Phase 2 | Non-Small Cell Lung Cancer Metastatic | - | - |
Carperitide | Phase 2 | Heart Failure, Congestive | - | - |
Raludotatug deruxtecan | Phase 2 | Advanced Solid Tumor | - | - |
DS-5670a | Phase 2 | Covid19 | - | - |
HER3-DXd | Phase 2 | Advanced Solid Tumor | - | - |
SUN13834 | Phase 2 | Atopic Dermatitis | - | - |
CS-7017 | Phase 2 | Advanced Non-small Cell Lung Cancer (NSCLC) | - | - |
DU-176b tablets | Phase 2 | Atrial Fibrillation | - | - |
DS-7011a | Phase 2 | Systemic Lupus Erythematosus | - | - |
piclozotan | Phase 2 | Parkinson's Disease | - | - |
5 mg ASB17061 | Phase 2 | Atopic Dermatitis | - | - |
CS7017 tablets | Phase 2 | Metastatic Non-small Cell Lung Cancer | - | - |
soblidotin | Phase 2 | Lung Cancer | - | - |
Temozolomide | Phase 2 | Patients With Newly Diagnosed Glioblastoma | - | - |
DS-1211b | Phase 2 | Pseudoxanthoma Elasticum | - | - |
DS-8201a 5.4 mg/kg Q3W | Phase 2 | Advanced Colorectal Cancer | - | - |
DS-8500a 25 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Pregabalin capsules | Phase 2 | Pain | - | - |
VN-0200 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
DS-3939a | Phase 2 | Advanced Solid Tumor | - | - |
Pactimibe, CS-505 | Phase 2 | Coronary Heart Disease | - | - |
Valemetostat Tosylate | Phase 2 | Adult T-cell Leukemia/Lymphoma | - | - |
Quizartinib High Dose | Phase 2 | Acute Myeloid Leukemia | - | - |
CS7017 | Phase 2 | Colorectal Cancer | - | - |
DS-5141b | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Warfarin potassium tablets | Phase 2 | Atrial Fibrillation | - | - |
DS-1040b | Phase 2 | Acute Ischemic Stroke | - | - |
edoxaban tosylate | Phase 2 | Deep Vein Thrombosis | - | - |
CS-917 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
CS-1008 2 mg/kg | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
DS-1001b | Phase 2 | WHO Grade II Glioma | - | - |
AC220 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
Compound AC220 | Phase 2 | Acute Myeloid Leukemia | - | - |
Sitagliptin 100 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
SUN13837 injection | Phase 2 | Acute Spinal Cord Injury | - | - |
Ifinatamab deruxtecan (I-DXd) | Phase 2 | Advanced Solid Tumor | - | - |
Edoxaban (DU-176b) | Phase 2 | Atrial Fibrillation | - | - |
CS-1008 (humanized anti-DR5 antibody) | Phase 2 | Pancreatic Cancer | - | - |
DJ-927 | Phase 2 | Colorectal Cancer | - | - |
U3-1287 | Phase 2 | NSCLC (Advanced Non-small Cell Lung Cancer) | - | - |
10mg DS-8500a tablet | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Fludarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
DS3790a | Phase 2 | Hematological Malignancies | - | - |
DS-5565 tablet | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
SUN11031 20 μg/kg | Phase 2 | Cachexia | - | - |
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor | Phase 2 | Thrombosis | - | - |
PLX3397 | Phase 2 | Hodgkin Lymphoma | - | - |
Rivoglitazone HCl | Phase 2 | Type 2 Diabetes | - | - |
Aspirin | Phase 2 | Peripheral Arterial Disease | - | - |
CS-1008 | Phase 2 | Non-small Cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Daiichi Sankyo's drug pipeline?→
CatalystAlert tracks 122 drug candidates in Daiichi Sankyo's (DSKYF) pipeline across Phase 3, Phase 2. Its lead program is DS-1062a (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Daiichi Sankyo's next FDA catalyst?→
Daiichi Sankyo's (DSKYF) next tracked catalyst is a Phase 3 expected August 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DSKYF biotech catalysts?→
Add DSKYF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Daiichi Sankyo's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.